Skip to main content
Equibles

4521 · KAKEN PHARMACEUTIAL CO., LTD. · Financials

Use 4521 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4521.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
3,825 JPY -15 (-0.39%) At close · Nov 13
Rebalance outlook locked
Market Cap
144.85B JPY
Shares
37.87M
Volume · Nov 13 77.1K Avg daily vol (3M) 119.63K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
76.87B -18.3%
FY2026 Revenue FY2022–FY2026
Net Income
2.14B -84.6%
FY2026 Net Income FY2022–FY2026
Gross Margin
52.02% -10.2pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
-1.17% -23.5pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
-11.08B -137.2%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 76.87B 94.04B 72.04B 72.98B 76.03B
JPY 36.88B 35.5B 33.51B 33.43B 34.46B
JPY 39.99B 58.53B 38.54B 39.56B 41.58B
JPY -899M 21.03B 9.51B 8B 17.06B
JPY 2.31B 19.44B 9.8B 6.82B 13.89B
JPY 168M 5.49B 1.77B 1.38B 4.34B
JPY 2.14B 13.95B 8.03B 5.44B 9.55B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 30.72B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.